{"id":"exemestane-and-gnrh-analogue","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Vaginal dryness"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Bone loss/osteoporosis"}]},"_chembl":{"chemblId":"CHEMBL1200374","moleculeType":"Small molecule","molecularWeight":"296.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exemestane is an aromatase inhibitor that blocks the conversion of androgens to estrogen in peripheral tissues. The GnRH analogue induces ovarian suppression by downregulating the hypothalamic-pituitary-gonadal axis, reducing circulating estrogen levels. Together, they provide complementary endocrine therapy by eliminating estrogen from multiple sources.","oneSentence":"Exemestane suppresses estrogen production while a GnRH analogue suppresses ovarian function, providing dual hormonal blockade in premenopausal women with hormone receptor-positive breast cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:53.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer in premenopausal women (adjuvant or metastatic setting)"}]},"trialDetails":[{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT00066703","phase":"PHASE3","title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":2672},{"nctId":"NCT00066690","phase":"PHASE3","title":"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-12-17","conditions":"Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma","enrollment":3066},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT00963417","phase":"NA","title":"Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2009-08-03","conditions":"Breast Cancer, Osteoporosis","enrollment":119},{"nctId":"NCT03820830","phase":"PHASE3","title":"Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-08-27","conditions":"Breast Cancer Recurrent","enrollment":405},{"nctId":"NCT05861830","phase":"PHASE3","title":"Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-05-15","conditions":"Advanced Breast Cancer","enrollment":80},{"nctId":"NCT01989780","phase":"PHASE2","title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2014-01","conditions":"Metastatic Breast Cancer","enrollment":160},{"nctId":"NCT03078751","phase":"PHASE2","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-20","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT02603679","phase":"PHASE2","title":"Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2015-02","conditions":"Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor","enrollment":181},{"nctId":"NCT04659551","phase":"PHASE2","title":"Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2017-10-05","conditions":"Breast Cancer","enrollment":43},{"nctId":"NCT02592083","phase":"PHASE2","title":"Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2015-10","conditions":"Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor","enrollment":10},{"nctId":"NCT02592746","phase":"PHASE2","title":"A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2016-06","conditions":"Metastatic Breast Cancer","enrollment":182},{"nctId":"NCT02689921","phase":"PHASE2","title":"NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer","status":"UNKNOWN","sponsor":"Midwestern Regional Medical Center","startDate":"2016-04","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT01638247","phase":"PHASE3","title":"Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2012-08","conditions":"Male Breast Cancer","enrollment":56},{"nctId":"NCT03081234","phase":"PHASE3","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2018-03-31","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00066807","phase":"PHASE3","title":"Premenopausal Endocrine Responsive Chemotherapy Trial","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-08","conditions":"Breast Cancer","enrollment":29},{"nctId":"NCT00659373","phase":"PHASE3","title":"Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2007-12","conditions":"Breast Cancer, Fatigue, Sleep Disorders","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AROMASIN, TRENATONE, ZOLADEX."],"phase":"phase_3","status":"active","brandName":"Exemestane and GnRH analogue","genericName":"Exemestane and GnRH analogue","companyName":"GBG Forschungs GmbH","companyId":"gbg-forschungs-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exemestane suppresses estrogen production while a GnRH analogue suppresses ovarian function, providing dual hormonal blockade in premenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive breast cancer in premenopausal women (adjuvant or metastatic setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}